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1. Introduction
  Laryngeal cancer is the most common head and neck 
malignant tumor, in northeast part of China, the incidence 
of laryngeal cancer occupies the first position among 
malignant tumors in head and neck. Around the world, the 
laryngeal cancer accounts for about 1%-5% of whole body 
tumors incidence, occupies 11th position among malignant 
tumors in whole body, seriously endanger human life and 
health[1-3]. At present, surgery and radiation therapy are 
still the main method for the treatment of laryngeal cancer, 
surgery, endoscopic laser and radiotherapy has the very 
good curative effect for early laryngeal cancer, operation is 
the main method for the treatment of middle-late laryngeal 
cancer, with adjuvant treatments including chemotherapy 
and radiotherapy. A growing data suggest that cancer stem 
cells exist in the tumor, which is closely related to tumor’s 
recurrence, proliferation, metastasis and the failure of 
response to radiation and chemotherapy[4-7].
  CD133 molecules are the most widely studied specific 
biomarkers on the surface of cancer stem cells, have close 
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relationship with the proliferation and invasive ability of 
tumors. So effective killing the CD133+ stem cells would be to 
the key to reduce the postoperative recurrence and increase 
chemotherapy sensitivity[8]. Another study confirmed 
that[9], IL-24 has the function of the damage and induce 
tumor cell differentiation, but had no effect on normal cell 
growth and death. We used flow cytometry (FCM) to isolate 
CD133
+ Hep-2 cells from Hep-2 cells, transfected CD133+ 
Hep-2 cells with pIRES2-ZsGreen1-hIL-24 vector, and 
detected the expression of hIL-24 gene and its effect on the 
proliferation and apoptosis of CD133+ +Hep-2 tumor cells. 
2. Materials and methods
2.1. Main reagents
  RNA extraction kit, RT-PCR kit and Apoptosis detection 
kit were from Beyotime Biotech Co., LTD.; DNA Marker 
was purchased from Beijing TransGen Biotech Co., LTD.; 
Lipofectamin 2000 was bought from Invitrogen Company; 
PCR Master Mix (Taq DNA Polymerase, PCR Buffer, dNTP) 
and IL-24 rabbit anti human antibody was purchased from 
Abcam Company; Primary antibody: IL-24 monoclonal 
antibody was purchased from Wuhan Three Eagle 
Biological Technology Co., LTD.; Second antibody: goat 
anti mice was purchased from Cell Signaling Technology 
Co., LTD. CO2 automatic constant temperature incubator 
(SANYO, Japan); Inverted microscope (OLYMPUS, Japan); 
Flow cytometry instrument (EPICS-XL, the United States); 
Protein electrophoresis apparatus and transfer system (Bio-
rad, USA); The laser confocal microscope (Lavision Biotec 
German). 
2.2. Cell culture
2.2.1. Hep-2 cells recovery
  15 mL centrifuge tube were sterilized, complete medium 
(RPMI1640 with 10% fetal bovine serum) and cell cultures 
were placed in super clean workbench under ultraviolet 
light more than 30 min. 10 mL RPMI1640 complete medium 
was added in a 15 mL centrifuge tube; Hep-2 cryopreserved 
cells were placed in 37 曟 constant temperature water bath 
and were shaked to melt within 1 min. Hep-2 cells were 
moved into a centrifugal tube with 10 mL complete medium 
for centrifuge at 1 000 rpm. After 5 min, the clear liquid 
was abandoned; the cells in 1 mL complete medium were 
thoroughly suspended. The cell suspension was inoculated 
onto a 10 cm culture plate and added with 5 mL complete 
medium with fully blow. After completion of vaccination the 
culture plate was moved into CO2 incubator under constant 
temperature of 37 曟. The culture medium was removed 
the next day, and added with same amount of fresh culture 
medium after washing twice with PBS.
2.2.2. Subculture
  Cell morphology was observed everyday; density and 
adherence were also observed under inverted microscope. 
When growth density of Hep 2 cells reached about 90% of 
the plate area, the culture was abandoned and rinsed twice 
with PBS. Trypsin-EDTA solution was added (to submerged 
bottom cells) to the culture dish. The cells digested gradually 
turned round, trypsin-EDTA solution was quickly abandoned 
when cells floated. The same amount of RPMI1640 medium 
was added to terminate the digestion. Cell suspension was 
fully percussed, and then divided into 2 petri dishes, added 
with more than 5 mL complete medium to each plate for 
incubation with CO2 at a constant temperature of 37 曟, daily 
growth and adherence status were observed under inverted 
microscope.
2.2.3. Isolation of CD133+ Hep-2 cells
  Cells were centrifuged at 1 000 rpm for 5 min, suspended 
with RPMI1640 then counted. Rabbit anti human CD133 
polyclonal antibody (10 毺L/10
6
) was added to Hep-2 cells 
to incubate for 15 min at room temperature, away from light. 
It was washed with PBS twice, and then added with goat 
anti rabbit IgG labeled FITC (10 毺L/10
6
) for 15 min at room 
temperature, away from light, washed with PBS (5% BSA), 
and then suspended with PBS for cell separation. 
2.2.4. Transfection of pIRES2-ZsGreen1-hIL-24
  After FCM sorting cells, CD133+ Hep-2 was incubated in 
RPMI 1640 (10% FBS) with 5% CO2 at 37 曟. CD133
+ Hep-2 
was transfected with pIRES2-ZsGreen1-hIL-24 and 
pIRES2-ZsGreen1 vector respectively, grouping as CD133+ 
Hep-2-hIL-24 (group A,experimental group), CD133+ Hep-
2-C (group B, empty vector group) and CD133+ Hep-2 (group 
C, blank control group).
  CD133+ Hep 2 cells were sorted out and inoculated on 
three confocal laser petri dishes, containing 1 mL RPMI1640 
culture medium with 10% FBS in each dish (1伊105-2伊105 
cells), then the cells of three groups were moved in 5% CO2 
incubator at 37 曟 overnight to the logarithmic phase.
  Reagent a (single hole) included 1.5 mL sterile centrifuge 
tube, 50 毺L RPMI-1460 (excluding fetal bovine serum), 
1 毺g plasmid DNA. They were mixed and moved at room 
temperature for 5 min. Reagent b included 1.5 mL sterile 
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centrifuge tube, 50 毺L RPMI-1460 (excluding fetal bovine 
serum), 2 毺L liposome solution. Reagent c included mixture 
of reagents a and b, then was moved at room temperature for 
20 min.
  Culture medium was removed in petri dish, cells were 
washed with PBS twice. They were added with 1 mL 
RPMI-1640 medium (excluding fetal bovine serum) into 
100 毺L Reagent c, and moved into 5% CO2 incubator at 
37 曟 for 6 h. Culture medium was discarded, and was added 
with 1 mL RPMI-1640 medium containing 10% fetal bovine 
serum, followed by incubation for 48 h, then it was observed 
under LSCM.
2.3. Detection of mRNA expression of hIL-24 by RT-PCR
  Cells of CD133+ Hep-2-hIL-24 were collected (Group 
A,experimental group), CD133+ Hep-2-C (Group B,empty 
vector group) and CD133+ Hep-2(Group C, blank control 
group). Total mRNA was isolated by using Trizol method.
毬-actin gene served as the internal reference in group B 
and C, cDNA and DNA was amplified by using RT-PCR and 
PCR methods, respectively. 
  The culture medium was abandoned, added with 600 毺L
Trizol per hole to percuss the cells vigorously. Cells were 
placed at room temperature for 5 min,added with 0.2 mL 
chloroform to mix vigorously for 15 s, then placed at room 
temperature for 3 min, centrifuged at 12 000 rpm for 15 min.
The aquatic layer liquid was moved (about 0.4 mL) to a 
new EP tube, then added with 0.4 mL isopropyl alcohol 
and mixed at room temperature for 10 min. They were 
centrifuged at 12 000 rpm for 10 min, and supernatant was 
abandoned, to expose white precipitation at the bottom 
of EP tube. They were added with 1 mL 75% ethanol and 
mixed, centrifuged at 9 000 rpm for 5 min. Supernatant was 
abandoned, the extracts were placed at room temperature 
to dry for 5 min, percussed with 30 毺L DEPC repeatedly, 
then underwent 60 曟 water bath for 10 min. Concentration 
requirement was OD260/OD280=1.8-2. RNA concentration 
was CD133+ Hep-2-hIL-24 (A Group,experimental group)
389 ng/毺L; CD133
+ Hep-2-C (Group B, empty vector group) 
421 ng/毺L and CD133
+ Hep-2 (Group C, blank control group) 
456 ng/毺L.
2.4. RT-PCR 
  Extractions of total RNA in CD133+ Hep-2-hIL-24 (Group 
A, experimental group), CD133+ Hep-2-C (Group B, empty 
vector group) and CD133+ Hep-2 (Group C, blank control 
group) were applied in PCR reaction, with primer-initiated 
sequence purchased from Shanghai Sangon Biological 
Engineering Technology And Service Co., Ltd.
  hIL-24 sense primer P3: 5’-CGGTACCATGAATTTTCAACAAGGGC-3’; 
anti-sense primer P4  5’-GTCTAGACTAGAGCTTGTAGAATTTCT-3’, 
amplified fragments length was 621 bp.
  毬-actin sense primer P5: 5’-CCGACAGGATGCAGAAGGAGAT-3’, anti-
sense primer P6   5’-GTCAAGAAAGGGTGTAACGCAACT-3’, 
amplified fragments length was 300 bp.
  Agarose gel with concentration of 0.5 毺g/mL (1 g agarose 
in 10 mg/mL EB) was used for protein electrophoresis 
at the voltage condition of 4 V/cm below and current of 
40 mA above. Then the protein bands were detected and 
photographed under ultraviolet light. 
2.5. Detection of protein expression of hIL-24 by Western blot
  The hIL-24 proteins were extracted by sonifier cell 
disrupter and BCA method was used for concentration test. 
15 毺L sample was loaded to each hole, stacking gel at 
80 V for 30 min and separating gel at 120 V for 60 min. PVDF 
trarsmembran was carried out under constant IEC 200 mA 
for 1.5 h. PVDF membrane was immersed by 10 mL of TBST 
blocking buffer (10% skimmed milk) at room temperature for 
30 min. Primary antibody was overnight incubated at 4 曟, 
followed by secondary antibody incubation for 1 h. 
2.6. Drawing of cell growth curve in different concentration 
using MTT
  M T T  [ 3 - ( 4 , 5 - D i m e t h y l t h i a z o l - 2 - y l ) - 2 , 5 -
diphenyltetrazolium bromide] reagent (c=5 mg/mL) was 
added to each well and incubated at 5% CO2 , 37 曟overnight. 
Thereafter MTT solution was removed. After addition of 
150 毺L of DMSO the plates were incubated for 15 min at 
37 曟to dissolve the formazan crystals. Absorbance readings 
of DMSO extracts were performed at 570 nm. Growth curve 
was plotted using absorbances against growth time; survival 
fraction can be calculated using the following equations: 
survival fraction=(absorbance value of experimental group/ 
absorbance value of control group伊100%) .
2.7. Observation of cell apoptosis 
  FCM was used to examine the cell apoptosis in each group. 
Culture cells were washed twice with PBS, added with 
0.25% trypsin for digesting cells, then terminated with 1640 
cultures containing 10% fetal bovine serum. After cell count, 
the cell density was adjusted to (5-10)伊105/ mL, then 1 mL 
cell was centrifuged at 1 000 rpm, 4 曟 for 5 min. Liquid 
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supernatant was abandoned, added with 1 mL of prefrozen 
PBS. The cells were gently suspended, then centrifuged at 
1 000 rpm, 4 曟 for 5 min. The supernatant was abandoned, 
the cells were resuspended gently with 200 毺L binding 
buffer, heavy suspension cells, added with 10 毺L Annexin 
v and gently mixed with 5 毺L PI and cells were placed at 
room temperature for 15 min in the dark. 300 binding buffer 
was added for instant FCM test.
2.8. Statistical analysis
  SPSS17.0 statistical software was used for processing the 
data, measurement data was expressed as mean依sd, single 
factor ANOVA was used for the analysis of variance between 
groups, t test was applied in data analysis, P<0.05 was 
regarded as statistically significant difference.
3 Results
3.1. Transfection results of CD133+ Hep-2 through liposome 
2000 under FCM
  GFP activities were measured 48 h post-transfection by 
FCM. The uneven strength of GFP activities in group A and B 
indicated the difference in pIRES2-ZsGreen1 copy numbers 
between groups. There was no fluorescent in group C (Figure 
1). 
A
A
A
B
B
B
C
C
C
Group A
Group B
Group C
Figure 1. Transfection results of CD133+ Hep-2 through liposome 
2000 by FCM.
A: fluorescent microscopic observations; B: visible light and 
fluorescent microscopic observations; C: visible light microscopic 
observations.
3.2. Agarose gel electrophoresis detected the transcription 
level of hIL-24 gene 
  RNA was isolated from CD133+ Hep-2-hIL-24 (A group, 
experimental group), CD133+ Hep-2-C (group B, empty 
vector group) and CD133+ Hep-2 (group C, blank control 
group), transcripted into cDNA, PCR cloned hIL-24 gene 
and 毬-actin gene in group B and C. The PCR product was 
subjected to electrophoresis and the results showed a 750-
500 bp band in group A, corresponding to the 621 bp of hIL-24
gene length. There was no corresponding bands of 750-500 
bp in group B and C, brighter bands among 500-250 bp were 
visible (B1, C1), corresponding to the 300 bp of 毬-actin 
gene length, confirming the insertion of hIL-24 gene in group 
A, as shown in Figure 2. 
BI          M            A          B            C          CI              DNA  Mark
bp
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1 000
   750
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Figure 2. Agarose gel electrophoresis detected the transcription level 
of hIL-4 gene. 
3.3. hIL-24 gene expression by Western blot
  hIL-24 and 毬-actin expression were observed in 
CD133
+ Hep-2-hIL-24 (group A, experimental group), only 
expression of 毬-actin were observed in CD133
+ Hep-2-C 
(group B, empty vector group) and CD133+ Hep-2 (group C, 
blank control group) (Figure 3).
A                          B                          C
IL-24 (24 kD)
毬-actin (42 kD)
 
Figure 3. hIL-24 gene expression by Western blot.
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3.4. Cell proliferation rate 
  Results showed a significantly slow cell proliferation in 
CD133
+ Hep-2-hIL-24 (experimental group) compared to 
CD133
+ Hep 2 cells (blank control group) (P<0.05), which 
showed no significant difference compared to CD133+ Hep-2 
C (empty vector group), as shown in Figure 4.
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Figure 4. Cell growth curve. 
3.5. Effects of hIL-24 transfection on cell apoptosis of 
CD133+ Hep-2
  CD133+ Hep-2-hIL-24 (group A) showed a significantly 
higher apoptosis rate than CD133+ Hep-2-C (group B) and 
CD133
+ Hep-2 (group C) (P<0.05). There was no statistical 
difference between group B and group C, as shown in Table 
1 and Figure 5. 
Table 1
Effects of hIL-24 transfection on cell apoptosis of CD133+ Hep-2 (%).
 Groups  Normal cells  Apoptosis cells Necrotic cells 
  A                    57.25%依8.62      36.58%依6.35  6.17%依1.35
  B                    80.21%依6.25           17.41%依10.3  2.38%依0.85
  C 82.82%依5.98          15.79%依9.58  1.39%依0.56
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Figure 5. Apoptosis flow diagram. 
4. Discussion 
  Only a small proportion of cells in tumor has the potential 
of self-renewing and unlimited proliferation, and thus has 
a strong ability to progress into tumor and sustain tumor 
growth, based on cancer stem cell theory[10-14]. CD133 
molecules are widely studied as the specific biomarkers 
on the surface of cancer stem cells. CD133 marker can 
be used in the separation of a wide variety of tumor stem 
cells, including laryngeal cancer, colon cancer, prostate 
cancer, brain tumor, liver cancer and endometrial cancer. 
In our preliminary research work, we separated the CD133+ 
laryngeal cancer cells and confirmed that low concentration 
of CD133+ laryngeal cancer cells have high tumorigenic 
ability with high proliferation and invasive ability, so CD133+ 
laryngeal cancer cells can be identified as stem cells of 
laryngeal cancer. 
  Interleukin-24 (IL-24) is also known as melanoma 
differentiation associated gene-7 (mda-7), which can 
regulate immune response under normal physiological 
concentration, it shows unique antitumor properties at 
high concentration. IL-24 has antagonism for a variety of 
different tumor cells. Studies have found that[15-18], IL-
24 has targeting property in inducing differentiation and 
destruction of tumor cells, which means it has no effect on 
growth and death of normal cells[19-21].
  In this experiment, the author extracted the CD133 positive 
cells in Hep-2 laryngeal cancer cells andtransfected 
eukaryotic vector containing full length of IL-24 cDNA 
into CD133 positive cells, experimental intervented the 
expression of CD133 positive gene in laryngeal cancer 
cells, to observe biological changes laryngeal cancer cell 
after transfected by CD133. The results showed positive 
expression of IL-24 mRNA and protein. While the cancer 
cells without successfully transfection or transfected with 
empty vector had no expression of IL-24. The biological 
changes showed a decreased in vitro proliferation ability 
and a higher apoptotic rate in CD133 positive cells than the 
control group and empty plasmid transfection group (P<0.05).
This study confirmed that human IL-24 gene can inhibit 
proliferation of CD133 positive laryngeal cancer cells and 
induce their apoptosis.
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